National Academies Press: OpenBook

Biomarkers of Neuroinflammation: Proceedings of a Workshop (2018)

Chapter: Appendix B Workshop Agenda

« Previous: Appendix A References
Suggested Citation:"Appendix B Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2018. Biomarkers of Neuroinflammation: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/24854.
×

B

Workshop Agenda

BIOMARKERS OF NEUROINFLAMMATION: A WORKSHOP

March 20 and 21, 2017

National Academy of Sciences Building
2101 Constitution Avenue, NW | Washington, DC

Background: Innate and adaptive immunities have become very important areas of investigation for psychiatric disorders, neurological disorders, neurodevelopmental disorders, and neurodegeneration resulting from traumatic brain injury (TBI). For example, compelling genetic and other biological data are demonstrating critical roles of innate and adaptive immunity in Alzheimer’s disease pathogenesis. Several conferences and meetings are being held in this hot area, but it is not clear how best to translate recent findings to therapeutics; developing biomarkers that can be validated and used in clinical development and regulatory decision making is a critical step in this process. Many efforts are already under way to identify biomarkers of neuroinflammation, including biomarkers in cerebrospinal fluid (CSF) and blood, as well as positron emission tomography imaging agents for targets such as translocator protein. Given the intense activity in academic research and private-sector settings and across many nervous system disorders, there is an opportunity to take stock of current knowledge, provide a venue for coordination, and identify potential opportunities to advance work in this domain. This public workshop will bring together key stakeholders from government, academia, industry, and disease-focused organizations to explore and ad-

Suggested Citation:"Appendix B Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2018. Biomarkers of Neuroinflammation: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/24854.
×

vance efforts to identify biomarkers of neuroinflammation that can be validated and used in clinical development and regulatory decision making.

Workshop Objectives:

  • Provide an overview of current knowledge on the role of neuroinflammation in nervous system disorders—including psychiatric and neurological disorders, neurodevelopmental disorders, and neurodegeneration resulting from TBI—discuss the various definitions of neuroinflammation in use across the field, and the contribution of the peripheral and central nervous system (CNS) innate immune systems to normal brain function and disease pathophysiology.
  • Explore the state of the science of neuroinflammation biomarkers and research needed to enable the use of these biomarkers at the individual level. Do any biomarkers undergoing development/validation implicate glia, neurons, immune cells, and/or endothelial cells? Should these be deployed singly or in combination, and where are the gaps in current approaches?
  • Facilitate coordination among consortia and companies that are developing biomarkers of neuroinflammation. How might a study be designed to establish the disease relevance or drug-development utility of a neuroinflammation biomarker? Are such studies under way, and if not, why not? If not, what more do we need to facilitate these, and are there opportunities for “add-on” studies to current clinical trials?
  • Highlight approaches, tools, and lessons learned that may apply across disorders and opportunities to advance the development of these biomarkers.

DAY 1: March 20, 2017, Room 120

1:00 p.m. Welcome and Overview of Workshop

RITA BALICE-GORDON, Sanofi (Co-Chair)

LINDA BRADY, National Institute of Mental Health (Co-Chair)

Suggested Citation:"Appendix B Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2018. Biomarkers of Neuroinflammation: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/24854.
×

Session Objectives:

  • Provide brief background information on inflammatory processes and the role of neuroinflammation in adaptive repair and protection as well as pathophysiology of the brain.
  • Survey current knowledge on the role of neuroinflammation in nervous system disorders—including psychiatric and neurological disorders, and neurodegeneration resulting from TBI—and common pathways for neuroinflammation across different disorders.
  • Discuss desirable biomarker characteristics for quantitatively tracking neuroinflammation in disease progression and therapeutic interventions in different CNS disorders.
1:15 p.m. Session Overview and Introduction

BRIAN CAMPBELL, MindImmune Therapeutics, Inc., and The University of Rhode Island (Moderator)

1:35 p.m. The Acute-to-Chronic Neuroinflammation Continuum

FIONA CRAWFORD, Roskamp Institute

AMIT BAR-OR, University of Pennsylvania

GARY LANDRETH, Case Western Reserve University

2:50 p.m. Break
3:05 p.m. The Acute-to-Chronic Neuroinflammation Continuum (continued)

BETH STEVENS, Boston Children’s Hospital

RICHARD DANEMAN, University of California, San Diego

3:55 p.m. Discussion
5:00 p.m. Adjourn Day 1
Suggested Citation:"Appendix B Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2018. Biomarkers of Neuroinflammation: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/24854.
×

DAY 2: March 21, 2017, Room 125

8:30 a.m. Welcome and Review of Day 1

RITA BALICE-GORDON, Sanofi (Co-Chair)

LINDA BRADY, National Institute of Mental Health (Co-Chair)

8:40 a.m. Keynote Presentation

EDWARD BULLMORE, University of Cambridge and GlaxoSmithKline

9:10 a.m. Discussion

PATRICIO O’DONNELL, Pfizer Neuroscience Research Unit (Moderator)

9:30 a.m. Break

Session Objectives:

  • Discuss current consortia, academic, and private-sector efforts to identify and validate imaging biomarkers of neuroinflammation and share methodological approaches and lessons learned.
  • Describe the use of neuroimaging biomarkers to identify changes in structure or tissue properties with respect to inflammation.
  • Address key issues relevant across CNS disorders, such as the following:
    • How well do neuroimaging methods differentiate between adaptive and pathological neuroinflammatory processes?
    • Are current imaging agents useful in identifying specific patient populations?
    • What is the potential clinical utility of imaging agents and can they detect immediate and longer-term changes following therapeutic interventions?
  • Describe the limitations of current imaging biomarkers of neuroinflammation and identify research and other potential next steps that would move the field forward.
Suggested Citation:"Appendix B Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2018. Biomarkers of Neuroinflammation: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/24854.
×
9:45 a.m. Session Overview

ANNA KATRIN SZARDENINGS, Johnson & Johnson (Moderator)

9:55 a.m. Presentations

ANNA KATRIN SZARDENINGS, Johnson & Johnson

ROBERT INNIS, National Institute of Mental Health

MARTINA ABSINTA, National Institute of Neurological Disorders and Stroke

KATERINA AKASSOGLOU, Gladstone Institute of Neurological Disease

11:10 a.m. Discussion
11:35 a.m. Lunch

Session Objectives:

  • Discuss current consortia, academic, and private-sector efforts to identify and validate CSF and other fluid biomarkers of neuroinflammation and share methodological approaches and lessons learned.
  • Address key issues relevant across CNS disorders, such as the following:
    • How well can CSF and other fluid biomarker detection methods differentiate between adaptive and pathological neuroinflammatory processes?
    • Are fluid biomarkers useful in identifying specific patient populations?
    • What is the potential clinical utility of fluid biomarkers and can they detect immediate and longer-term changes following therapeutic interventions?
    • How reliable are peripheral biomarkers as indicators of neuroinflammation?
Suggested Citation:"Appendix B Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2018. Biomarkers of Neuroinflammation: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/24854.
×
  • Describe the limitations of current fluid biomarkers of neuroinflammation and identify research and other potential next steps that would move the field forward.
  • Explore the relationship between fluid and imaging biomarkers.
12:35 p.m. Session Overview

ELIEZER MASLIAH, National Institute on Aging (Moderator)

12:45 p.m. Presentations

BRIAN CAMPBELL, MindImmune Therapeutics, Inc., and The University of Rhode Island

RICHARD PERRIN, Washington University in St. Louis

STEVEN MCCARROLL, Harvard Medical School

1:45 p.m. Discussion
2:10 p.m. Break

Session Objectives:

  • Highlight key themes from the workshop.
  • Discuss approaches, tools, and lessons learned that may apply across disorders and opportunities to advance the development of these biomarkers.
  • Identify specific barriers and opportunities for increased coordinating among ongoing efforts in academia, the private sector, and consortia.
  • Brainstorm potential collaborative projects that could be submitted through the Biomarkers Consortium or other current or planned mechanisms.
  • Consider potential regulatory issues for biomarkers of neuroinflammation as research, development, and validation move forward.
Suggested Citation:"Appendix B Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2018. Biomarkers of Neuroinflammation: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/24854.
×
2:25 p.m. Session Overview

LINDA BRADY, National Institute of Mental Health

RITA BALICE-GORDON, Sanofi

2:35 p.m. Panel Remarks

EDWARD BULLMORE, University of Cambridge and GlaxoSmithKline

GARY LANDRETH, Case Western Reserve University

RICHARD PERRIN, Washington University in St. Louis

AMIT BAR-OR, University of Pennsylvania

ANNA KATRIN SZARDENINGS, Johnson & Johnson

ANDREW MILLER, Emory University

TAREK SAMAD, Pfizer Inc.

3:45 p.m. Discussion
4:30 p.m. Adjourn Workshop
Suggested Citation:"Appendix B Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2018. Biomarkers of Neuroinflammation: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/24854.
×

This page intentionally left blank.

Suggested Citation:"Appendix B Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2018. Biomarkers of Neuroinflammation: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/24854.
×
Page 63
Suggested Citation:"Appendix B Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2018. Biomarkers of Neuroinflammation: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/24854.
×
Page 64
Suggested Citation:"Appendix B Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2018. Biomarkers of Neuroinflammation: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/24854.
×
Page 65
Suggested Citation:"Appendix B Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2018. Biomarkers of Neuroinflammation: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/24854.
×
Page 66
Suggested Citation:"Appendix B Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2018. Biomarkers of Neuroinflammation: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/24854.
×
Page 67
Suggested Citation:"Appendix B Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2018. Biomarkers of Neuroinflammation: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/24854.
×
Page 68
Suggested Citation:"Appendix B Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2018. Biomarkers of Neuroinflammation: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/24854.
×
Page 69
Suggested Citation:"Appendix B Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2018. Biomarkers of Neuroinflammation: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/24854.
×
Page 70
Next: Appendix C Registered Attendees »
Biomarkers of Neuroinflammation: Proceedings of a Workshop Get This Book
×
Buy Paperback | $50.00 Buy Ebook | $40.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

Neuroinflammation is a burgeoning area of interest in academia and biopharma, with a broadly acknowledged role in many central nervous system (CNS) disorders. However, there is little agreement on the pathophysiological mechanisms that underlie the manifestations of neuroinflammation in the CNS compartment and how neuroinflammation operates as a driver and also as a consequence of disease in the brain. Moreover, another unclear area is how to translate increased understanding of the mechanisms that underlie neuroinflammation and its manifestations in the CNS to therapeutics.

To address these gaps in understanding mechanisms and how to translate that understanding into therapeutics, the Forum on Neuroscience and Nervous System Disorders of the National Academies of Sciences, Engineering, and Medicine convened a workshop on March 20-21, 2017, bringing together key leaders in the field from industry, academia, and governmental agencies to explore the role and mechanisms of neuroinflammation in a variety of CNS diseases. The workshop also considered strategies to advance the identification and validation of biomarkers of neuroinflammation that could accelerate development of therapies, bringing much-needed treatments to patients with disorders ranging from neuroinflammatory diseases such as multiple sclerosis (MS) to neuropsychiatric disorders such as depression. This publication summarizes the presentations and discussions from the workshop.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!